Citigroup cuts target for BridgeBio Pharma stock to USD 91.00

Published on 10/20/2026 at 20:33 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Analysts average USD 104.90 across 24 firms with a Moderate Buy rating on October 19, 2026. BBIO stock costs EUR 60.12 on October 20, 2026.

Reporting date October 28, 2026

Citigroup cut its BridgeBio Pharma target on October 19, 2026.
BridgeBio Pharma reported USD 243.68 million in second-quarter revenue, up 120.40 percent year over year.
BridgeBio Pharma stock costs EUR 60.12 at Lang & Schwarz on October 20, 2026 at 8:30 p.m. CEST and sits 25.25 percent below its EUR 80.73 52-week high.
BridgeBio Pharma is scheduled to report third-quarter results on October 28, 2026.

BBIO, US10806X1028, Illustration mit AI erstellt.

Citigroup cut its BridgeBio Pharma price target from USD 94.00 to USD 91.00 while keeping a neutral rating in a report dated October 19, 2026, according to MarketBeat. The target is 34.70 percent above the USD 67.56 Nasdaq price on October 20, 2026 at 2:31 p.m. ET, calculated from the two dollar values. BridgeBio Pharma stock was trading at EUR 60.12 at Lang & Schwarz on October 20, 2026 at 8:30 p.m. CEST.

Citigroup lowers its target

The change leaves Citigroup below the broader analyst average. MarketBeat reported an average target of USD 104.90 from 24 analysts on October 19, 2026, alongside a Moderate Buy consensus. That average stands USD 13.90 above Citigroup's new target, making the bank's neutral stance more cautious than the aggregate view.

Stock remains below its yearly high

BridgeBio Pharma's euro quotation sits inside a EUR 45.18 to EUR 80.73 52-week range on October 20, 2026. At EUR 60.12, the stock is 25.25 percent below the high and 33.07 percent above the low. The primary Nasdaq quote was USD 67.56 at 2:31 p.m. ET on the same date, while the finance data showed a market capitalization of USD 13.2 billion.

Revenue grew in the second quarter

BridgeBio Pharma reported USD 243.68 million in revenue for the second quarter of 2026, a 120.40 percent increase from the same quarter a year earlier. Net income was a loss of USD 155.89 million and diluted earnings per share were negative USD 0.78 for that period, according to Business Quant. The revenue increase therefore came with a substantial quarterly loss.

When are the next results due?

BridgeBio Pharma is scheduled to report third-quarter 2026 results on October 28, 2026. Yahoo Finance lists the earnings event at 8:00 p.m. UTC, which corresponds to 4:00 p.m. ET. The date gives investors the next stated checkpoint for revenue, cash use and the development pipeline.

Price and investor perspective

The current euro quote places the stock well below its yearly high, while the latest quarterly revenue comparison shows rapid expansion alongside continued losses. Citigroup's lower USD 91.00 target remains above the Nasdaq price, but it is below the USD 104.90 analyst average.

The further course of trading is shown by the continuously updated real-time quote of BBIO stock.